Positioning new pharmacotherapies for COPD

References

• VestboJHurdSSAgustíAGGlobal strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summaryAm J Respir Crit Care Med2013187434736522878278
   PubMed Web of Science ®Google Scholar
• SiedlinskiMTingleyDLipmanPJCOPDGene and ECLIPSE InvestigatorsDissecting direct and indirect genetic effects on chronic obstructive pulmonary disease (COPD) susceptibilityHum Genet2013132443144123299987
   PubMed Web of Science ®Google Scholar
• SchikowskiTMillsICAndersonHRAmbient air pollution: a cause of COPD?Eur Respir J201443125026323471349
   PubMed Web of Science ®Google Scholar
• ManninoDMBuistASGlobal burden of COPD: risk factors, prevalence, and future trendsLancet2007370958976577317765526
   PubMed Web of Science ®Google Scholar
• HalbertRJNatoliJLGanoABadamgaravEBuistASManninoDMGlobal burden of COPD: systematic review and meta-analysisEur Respir J200628352353216611654
   PubMed Web of Science ®Google Scholar
• LozanoRNaghaviMForemanKGlobal and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010Lancet201238098592095212823245604
   PubMed Web of Science ®Google Scholar
• GuarascioAJRaySMFinchCKSelfTHThe clinical and economic burden of chronic obstructive pulmonary disease in the USAClinicoecon Outcomes Res2013523524523818799
   PubMedGoogle Scholar
• AnthonisenNRConnettJEMurrayRPSmoking and lung function of Lung Health Study participants after 11 yearsAm J Respir Crit Care Med2002166567567912204864
   PubMed Web of Science ®Google Scholar
• ManWDPolkeyMIDonaldsonNGrayBJMoxhamJCommunity pulmonary rehabilitation after hospitalisation for acute exacerbations of chronic obstructive pulmonary disease: randomised controlled studyBMJ20043297476120915504763
   PubMed Web of Science ®Google Scholar
• NaunheimKSWoodDEMohsenifarZNational Emphysema Treatment Trial Research GroupLong-term follow-up of patients receiving lung-volume-reduction surgery versus medical therapy for severe emphysema by the National Emphysema Treatment Trial Research GroupAnn Thorac Surg200682243144316888872
   PubMed Web of Science ®Google Scholar
• HosenpudJDBennettLEKeckBMEdwardsEBNovickRJEffect of diagnosis on survival benefit of lung transplantation for end-stage lung diseaseLancet1998351909524279433425
   PubMed Web of Science ®Google Scholar
• CooperCBBarjaktarevicIZA new algorithm for the management of COPDLancet Respir Med20153426626825890644
   PubMed Web of Science ®Google Scholar
• CooperCBTashkinDPRecent developments in inhaled therapy in stable chronic obstructive pulmonary diseaseBMJ2005330749264064415774995
   PubMed Web of Science ®Google Scholar
• CelliBRMacNeeWATS/ERS Task ForceStandards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paperEur Respir J200423693294615219010
   PubMed Web of Science ®Google Scholar
• BTS guidelines for the management of chronic obstructive pulmonary diseaseThe COPD Guidelines Group of the Standards of Care Committee of the BTSThorax199752Suppl 5S1S28
   PubMed Web of Science ®Google Scholar
• O’DonnellDEHernandezPKaplanACanadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease – 2008 update – highlights for primary careCan Respir J200815Suppl A1A8A
   PubMed Web of Science ®Google Scholar
• BatemanEDHurdSSBarnesPJGlobal strategy for asthma management and prevention: GINA executive summaryEur Respir J200831114317818166595
   PubMed Web of Science ®Google Scholar
• ChungKFWenzelSEBrozekJLInternational ERS/ATS guidelines on definition, evaluation and treatment of severe asthmaEur Respir J201443234337324337046
   PubMed Web of Science ®Google Scholar
• CelliBRBarnesPJExacerbations of chronic obstructive pulmonary diseaseEur Respir J20072961224123817540785
   PubMed Web of Science ®Google Scholar
• CooperCBCelliBRJardimJRTreadmill endurance during 2-year treatment with tiotropium in patients with COPD: a randomized trialChest2013144249049723558890
   PubMed Web of Science ®Google Scholar
• CasaburiRKukafkaDCooperCBWitekTJJrKestenSImprovement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPDChest2005127380981715764761
   PubMed Web of Science ®Google Scholar
• TashkinDPCelliBSennSUPLIFT Study InvestigatorsA 4-year trial of tiotropium in chronic obstructive pulmonary diseaseN Engl J Med2008359151543155418836213
   PubMed Web of Science ®Google Scholar
• CalverleyPPauwelsRVestboJTRial of Inhaled STeroids ANd long-acting beta2 agonists study groupCombined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trialLancet2003361935644945612583942
   PubMed Web of Science ®Google Scholar
• PauwelsRALöfdahlCGLaitinenLALong-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary DiseaseN Engl J Med1999340251948195310379018
   PubMed Web of Science ®Google Scholar
• VestboJSørensenTLangePBrixATorrePViskumKLong-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trialLancet199935391671819182310359405
   PubMed Web of Science ®Google Scholar
• Lung Health Study Research GroupEffect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary diseaseN Engl J Med2000343261902190911136260
   PubMed Web of Science ®Google Scholar
• SzafranskiWCukierARamirezAEfficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary diseaseEur Respir J2003211748112570112
   PubMed Web of Science ®Google Scholar
• CrimCCalverleyPMAndersonJAPneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study resultsEur Respir J200934364164719443528
   PubMed Web of Science ®Google Scholar
• SinghSAminAVLokeYKLong-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysisArch Intern Med2009169321922919204211
   PubMed Web of Science ®Google Scholar
• Novartis PharmaceuticalsStudy to Evaluate the Efficacy and Safety of Glycopyrronium or Indacaterol Maleate and Glycopyrronium Bromide Fixed-dose Combination Regarding Symptoms and Health Status in Patients With Moderate COPD Switching From Treatment With Any Standard COPD Regimen Available from: https://clinicaltrials.gov/ct2/show/NCT1985334. NLM identifier: NCT1985334Accessed June 17, 2015
   Google Scholar
• GlaxoSmithKlineSafety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of GSK573719 (LAMA) and GW642444 (LABA) Administered Individually and Concurrently in Healthy Japanese Subjects (DB2113208) Available from: https://clinicaltrials.gov/ct2/show/NCT0976144?term=NCT0976144&rank=1. NLM identifier: NCT0976144Accessed June 17, 2015
   Google Scholar
• GlaxoSmithKlinePharmacokinetics Of Umeclidinium and Vilanterol in Healthy Chinese, a Randomized, Open Label, 3 Crossover Study Available from: https://clinicaltrials.gov/ct2/show/NCT1899638?term=NCT1899638&rank=1. NLM identifier: NCT1899638Accessed June 17, 2015
   Google Scholar
• GlaxoSmithKlineA Study to Evaluate the Effect of Umeclidinium (UMEC) as Combination Therapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Available from: https://clinicaltrials.gov/ct2/show/NCT2257372?term=NCT2257372&rank=1. NLM identifier: NCT2257372Accessed June 17, 2015
   Google Scholar
• JonesPWSinghDBatemanEDEfficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN studyEur Respir J201240483083622441743
   PubMed Web of Science ®Google Scholar
• KerwinEMD’UrzoADGelbAFLakkisHGarcia GilECaractaCFACCORD I study investigatorsEfficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I)COPD2012929010122320148
   PubMedGoogle Scholar
• FuhrRMagnussenHSaremKEfficacy of aclidinium bromide 400 μg twice daily compared with placebo and tiotropium in patients with moderate to severe COPDChest2012141374575221903737
   PubMed Web of Science ®Google Scholar
• JoosGFPotential for long-acting muscarinic antagonists in chronic obstructive pulmonary diseaseExpert Opin Investig Drugs2010192257264
   PubMed Web of Science ®Google Scholar
• RennardSIScanlonPDFergusonGTACCORD COPD II: a randomized clinical trial to evaluate the 12-week efficacy and safety of twice-daily aclidinium bromide in chronic obstructive pulmonary disease patientsClin Drug Investig20133312893904
   PubMed Web of Science ®Google Scholar
• GelbAFTashkinDPMakeBJZhongXGarcia GilECaractaCLAS-MD-35 study investigatorsLong-term safety and efficacy of twice-daily aclidinium bromide in patients with COPDRespir Med2013107121957196523916502
   PubMed Web of Science ®Google Scholar
• D’UrzoAKerwinERennardSHeTGarcia GilECaractaCOne-year extension study of ACCORD COPD I: safety and efficacy of two doses of twice-daily aclidinium bromide in patients with COPDCOPD201310450051023679347
   PubMedGoogle Scholar
• JonesPWRennardSIAgustiAEfficacy and safety of once-daily aclidinium in chronic obstructive pulmonary diseaseRespir Res2011125521518460
   PubMed Web of Science ®Google Scholar
• ChanezPBurgePSDahlRAclidinium bromide provides long-acting bronchodilation in patients with COPDPulm Pharmacol Ther2010231152119683590
   PubMed Web of Science ®Google Scholar
• KerwinEHébertJGallagherNEfficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 studyEur Respir J20124051106111423060624
   PubMed Web of Science ®Google Scholar
• D’UrzoAFergusonGTvan NoordJAEfficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trialRespir Res20111215622151296
   PubMed Web of Science ®Google Scholar
• VerkindreCFukuchiYFlémaleASustained 24-h efficacy of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patientsRespir Med2010104101482148920541381
   PubMed Web of Science ®Google Scholar
• VogelmeierCVerkindreCCheungDSafety and tolerability of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patientsPulm Pharmacol Ther201023543844420416390
   PubMed Web of Science ®Google Scholar
• UlrikCSOnce-daily glycopyrronium bromide, a long-acting muscarinic antagonist, for chronic obstructive pulmonary disease: a systematic review of clinical benefitInt J Chron Obstruct Pulmon Dis2012767367823055716
   PubMed Web of Science ®Google Scholar
• Tal-SingerRCahnAMehtaRInitial assessment of single and repeat doses of inhaled umeclidinium in patients with chronic obstructive pulmonary disease: two randomised studiesEur J Pharmacol20137011–3404823276660
   PubMed Web of Science ®Google Scholar
• TrivediRRichardNMehtaRChurchAUmeclidinium in patients with COPD: a randomised, placebo-controlled studyEur Respir J2014431728123949963
   PubMed Web of Science ®Google Scholar
• FeldmanGWalkerRRBrooksJMehtaRCraterG28-Day safety and tolerability of umeclidinium in combination with vilanterol in COPD: a randomized placebo-controlled trialPulm Pharmacol Ther201225646547122955035
   PubMed Web of Science ®Google Scholar
• BattramCCharltonSJCuenoudBIn vitro and in vivo pharmacological characterization of 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one (indacaterol), a novel inhaled beta(2) adrenoceptor agonist with a 24-h duration of actionJ Pharmacol Exp Ther2006317276277016434564
   PubMed Web of Science ®Google Scholar
• MahlerDAD’UrzoABatemanEDINTRUST-1 and INTRUST-2 study investigatorsConcurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparisonThorax201267978178822544891
   PubMed Web of Science ®Google Scholar
• DahlRChungKFBuhlRINVOLVE (INdacaterol: Value in COPD: Longer Term Validation of Efficacy and Safety) Study InvestigatorsEfficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPDThorax201065647347920522841
   PubMed Web of Science ®Google Scholar
• KornmannODahlRCentanniSINLIGHT-2 (Indacaterol Efficacy Evaluation Using 150-μg Doses with COPD Patients) study investigatorsOnce-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparisonEur Respir J201137227327920693243
   PubMed Web of Science ®Google Scholar
• KornSKerwinEAtisSAmosCOwenRLassenCINSIST study groupIndacaterol once-daily provides superior efficacy to salmeterol twice-daily in COPD: a 12-week studyRespir Med2011105571972621367594
   PubMed Web of Science ®Google Scholar
• BuhlRDunnLJDisdierCINTENSITY study investigatorsBlinded 12-week comparison of once – daily indacaterol and tiotropium in COPDEur Respir J201138479780321622587
   PubMed Web of Science ®Google Scholar
• ChapmanKRRennardSIDograAOwenRLassenCKramerBINDORSE Study InvestigatorsLong-term safety and efficacy of indacaterol, a long-acting β2-agonist, in subjects with COPD: a randomized, placebo-controlled studyChest20111401687521349928
   PubMed Web of Science ®Google Scholar
• O’DonnellDECasaburiRVinckenWINABLE 1 study groupEffect of indacaterol on exercise endurance and lung hyperinflation in COPDRespir Med201110571030103621498063
   PubMed Web of Science ®Google Scholar
• DecramerMRossiALawrenceDMcBryanDIndacaterol therapy in patients with COPD not receiving other maintenance treatmentRespir Med2012106121706171423031496
   PubMed Web of Science ®Google Scholar
• DonohueJFSinghDKornmannOLawrenceDLassenCKramerBSafety of indacaterol in the treatment of patients with COPDInt J Chron Obstruct Pulmon Dis2011647749222003293
   PubMed Web of Science ®Google Scholar
• KhindriSSaboRHarrisSWoessnerRJenningsSDrollmannAFCardiac safety of indacaterol in healthy subjects: a randomized, multidose, placebo- and positive-controlled, parallel-group thorough QT studyBMC Pulm Med2011113121615886
   PubMed Web of Science ®Google Scholar
• ChowdhuryBASeymourSMMicheleTMDurmowiczAGLiuDRosebraughCJThe risks and benefits of indacaterol – the FDA’s reviewN Engl J Med2011365242247224922168640
   PubMed Web of Science ®Google Scholar
• HananiaNAFeldmanGZachgoWThe efficacy and safety of the novel long-acting β2 agonist vilanterol in patients with COPD: a randomized placebo-controlled trialChest2012142111912722241764
   PubMed Web of Science ®Google Scholar
• LötvallJBatemanEDBleeckerER24-h duration of the novel LABA vilanterol trifenatate in asthma patients treated with inhaled corticosteroidsEur Respir J201240357057922362859
   PubMed Web of Science ®Google Scholar
• SlackRJBarrettVJMorrisonVSIn vitro pharmacological characterization of vilanterol, a novel long-acting β2-adrenoceptor agonist with 24-hour duration of actionJ Pharmacol Exp Ther2013344121823023131596
   PubMed Web of Science ®Google Scholar
• McKeageKFluticasone furoate/vilanterol: a review of its use in chronic obstructive pulmonary diseaseDrugs201474131509152225074268
   PubMed Web of Science ®Google Scholar
• CazzolaMPageCPRoglianiPMateraMGβ2-agonist therapy in lung diseaseAm J Respir Crit Care Med2013187769069623348973
   PubMed Web of Science ®Google Scholar
• PepinJLCockcroftJRMidwinterDSharmaSRubinDBAndreasSLong-acting bronchodilators and arterial stiffness in patients with COPD: a comparison of fluticasone furoate/vilanterol with tiotropiumChest201414661521153025058845
   PubMed Web of Science ®Google Scholar
• CelliBCraterGKilbrideSOnce-daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled studyChest Epub201412
   Web of Science ®Google Scholar
• DecramerMAnzuetoAKerwinEEfficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trialsLancet Respir Med20142647248624835833
   PubMed Web of Science ®Google Scholar
• DransfieldMTBourbeauJJonesPWOnce-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trialsLancet Respir Med20131321022324429127
   PubMed Web of Science ®Google Scholar
• US Food Drug AdministrationFDA approves Anoro Ellipta to treat chronic obstructive pulmonary disease [press release]Silver Spring, MDUS Food and Drug Administration20131218 Available from: http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm379057.htmAccessed June 17, 2015
   Google Scholar
• van NoordJASmeetsJJDrenthBM24-hour bronchodilation following a single dose of the novel β(2)-agonist olodaterol in COPDPulm Pharmacol Ther201124666667221839850
   PubMed Web of Science ®Google Scholar
• CazzolaMCalzettaLMateraMGβ(2)–adrenoceptor agonists: current and future directionBr J Pharmacol2011163141721232045
   PubMed Web of Science ®Google Scholar
• O’ByrnePMvan der LindeJCockcroftDWProlonged bronchoprotection against inhaled methacholine by inhaled BI 1744, a long-acting beta(2)-agonist, in patients with mild asthmaJ Allergy Clin Immunol200912461217122120004781
   PubMed Web of Science ®Google Scholar
• KochAPizzichiniEHamiltonALung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat® versus placebo and formoterol twice daily in patients with GOLD 2–4 COPD: results from two replicate 48-week studiesInt J Chron Obstruct Pulmon Dis2014969771425045258
   PubMed Web of Science ®Google Scholar
• ProfitaMAlbanoGDRiccobonoLIncreased levels of Th17 cells are associated with non-neuronal acetylcholine in COPD patientsImmunobiology2014219539240124529390
   PubMed Web of Science ®Google Scholar
• FergusonGTFeldmanGJHofbauerPEfficacy and safety of olodaterol once daily delivered via Respimat® in patients with GOLD 2–4 COPD: results from two replicate 48-week studiesInt J Chron Obstruct Pulmon Dis2014962964524966672
   PubMed Web of Science ®Google Scholar
• TimmerWMassanaEJimenezESeoaneBde MiquelGRuizSFirst-in-human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of abediterol (LAS100977), a novel long-acting Β2-agonistJ Clin Pharmacol201454121347135324989946
   PubMed Web of Science ®Google Scholar
• CazzolaMRoglianiPSegretiAMateraMGAn update on bronchodilators in Phase I and II clinical trialsExpert Opin Investig Drugs2012211014891501
   PubMed Web of Science ®Google Scholar
• BroadleyKJBeta-adrenoceptor responses of the airways: for better or worse?Eur J Pharmacol20065331–3152716469310
   PubMed Web of Science ®Google Scholar
• KempsfordRNorrisVSiedererSVilanterol trifenatate, a novel inhaled long-acting beta2 adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPDPulm Pharmacol Ther201326225626423232038
   PubMed Web of Science ®Google Scholar
• TashkinDPFergusonGTCombination bronchodilator therapy in the management of chronic obstructive pulmonary diseaseRespir Res2013144923651244
   PubMed Web of Science ®Google Scholar
• CazzolaMCentanniSSantusPThe functional impact of adding salmeterol and tiotropium in patients with stable COPDRespir Med200498121214122115588043
   PubMed Web of Science ®Google Scholar
• CazzolaMSegretiAMateraMGNew developments in the combination treatment of COPD: focus on umeclidinium/vilanterolDrug Des Devel Ther2013712011208
   PubMed Web of Science ®Google Scholar
• KellyEUmeclidinium bromide and vilanterol in combination for the treatment of chronic obstructive pulmonary diseaseExpert Rev Clin Pharmacol20147440341324909949
   PubMed Web of Science ®Google Scholar
• DonohueJFNiewoehnerDBrooksJO’DellDChurchASafety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, double-blind, placebo-controlled studyRespir Res2014157825015176
   PubMed Web of Science ®Google Scholar
• KelleherDTombsLPreeceABrealeyNMehtaRA randomized, placebo- and moxifloxacin-controlled thorough QT study of umeclidinium monotherapy and umeclidinium/vilanterol combination in healthy subjectsPulm Pharmacol Ther2014291495725020273
   PubMed Web of Science ®Google Scholar
• RodrigoGJPlazaVEfficacy and safety of a fixed-dose combination of indacaterol and Glycopyrronium for the treatment of COPD: a systematic reviewChest2014146230931724556877
   PubMed Web of Science ®Google Scholar
• VinckenWAumannJChenHHenleyMMcBryanDGoyalPEfficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 studyInt J Chron Obstruct Pulmon Dis2014921522824596459
   PubMed Web of Science ®Google Scholar
• BatemanEDFergusonGTBarnesNDual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE studyEur Respir J20134261484149423722616
   PubMed Web of Science ®Google Scholar
• RodrigoGJPlazaVEfficacy and safety of indacaterol and Glycopyrronium in COPD: an updateChest20141462e7525091780
   PubMed Web of Science ®Google Scholar
• CazzolaMRoglianiPMateraMGAclidinium bromide/formoterol fumarate fixed-dose combination for the treatment of chronic obstructive pulmonary diseaseExpert Opin Pharmacother203;146755781
   Web of Science ®Google Scholar
• Pearl Therapeutics, IncStudy to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD Available from: https://clinicaltrials.gov/ct2/show/NCT2343458?term=NCT2343458&rank=1. NLM identifier: NCT2343458Accessed June 11, 2015
   Google Scholar
• Pearl Therapeutics, IncCrossover Study to Assess the Efficacy of PT003 With and Without a Valved Holding Chamber in Subjects With Moderate to Severe COPD Available from: https://clinicaltrials.gov/ct2/show/NCT2454959?term=NCT2454959&rank=1. NLM identifier: NCT2454959Accessed June 11, 2015
   Google Scholar
• Pearl Therapeutics, Inc24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003 and Placebo MDI Available from: https://clinicaltrials.gov/ct2/show/NCT2347085?term=NCT2347085&rank=1. NLM identifier: NCT2347085Accessed June 11, 2015
   Google Scholar
• Pearl Therapeutics, Inc24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003, Open-Label Spiriva^® Respimat^® as an Active Control, and Placebo Available from: https://clinicaltrials.gov/ct2/show/NCT2347072?term=NCT2347072&rank=1. NLM identifier: NCT2347072Accessed June 11, 2015
   Google Scholar
• Pearl Therapeutics, Inc24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003, Open-Label Spiriva^® Respimat^® as an Active Control, and Placebo Available from: https://clinicaltrials.gov/ct2/show/NCT2347072?term=NCT2347072&rank=1. NLM identifier: NCT2347072Accessed June 11, 2015
   Google Scholar
• Pearl Therapeutics, IncGlycopyrronium and Formoterol Fumarate (GFF) Metered Dose Inhaler (MDI) Dose Indicator Study in Adults With Moderate to Very Severe COPD Available from: https://clinicaltrials.gov/ct2/show/NCT2268396?term=NCT2268396&rank=1. NLM identifier: NCT2268396Accessed June 11, 2015
   Google Scholar
• ReisnerCFogartyCSpangenthalSDunnLKerwinEMQuinnDNovel combination of glycopyrrolate and formoterol MDI (GFF-MDI) provides superior bronchodilation compared to its components administered alone, tiotropium DPI, and formoterol DPI in a randomized, double-blind, placebo-controlled phase 2b study in patients with COPD [abstract]Am J Respir Crit Care Med2011183A6453
   Web of Science ®Google Scholar
• ReisnerCSt RoseEStromSFixed combination of glycopyrrolate and formoterol MDI (GFF-MDI) demonstrates superior inspiratory capacity (IC) compared to tiotropium DPI (Tio) following 7 days dosing, in a randomized, double-blind, placebo-controlled phase 2b study in patients with COPD [abstract P879]Eur Respir J201138Suppl 55150s
   Google Scholar
• TammMRichardsDHBeghéBFabbriLInhaled corticosteroid and long-acting β2-agonist pharmacological profiles: effective asthma therapy in practiceRespir Med2012106Suppl 1S9S1923273165
   PubMed Web of Science ®Google Scholar
• NelsonHSChapmanKRPykeSDJohnsonMPritchardJNEnhanced synergy between fluticasone propionate and salmeterol inhaled from a single inhaler versus separate inhalersJ Allergy Clin Immunol20031121293612847476
   PubMed Web of Science ®Google Scholar
• KewKMDiasSCatesCJLong-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysisCochrane Database Syst Rev20143CD01084424671923
   PubMed Web of Science ®Google Scholar
• DongYHLinHHShauWYWuYCChangCHLaiMSComparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison meta-analysis of randomised controlled trialsThorax2013681485623042705
   PubMed Web of Science ®Google Scholar
• US Food Drug AdministrationNovel New Drugs 2013 SummarySilver Spring, MDUS Food and Drug Administration2014 Available from: http://www.fda.gov/downloads/drugs/developmentapprovalprocess/druginnovation/ucm381803.pdfAccessed June 17, 2015
   Google Scholar
• DransfieldMTFeldmanGKorenblatPEfficacy and safety of once-daily fluticasone furoate/vilanterol (100/25 mcg) versus twice-daily fluticasone propionate/salmeterol (250/50 mcg) in COPD patientsRespir Med201410881171117924998880
   PubMed Web of Science ®Google Scholar
• CazzolaMMateraMGEmerging inhaled bronchodilators: an updateEur Respir J200934375776919720811
   PubMed Web of Science ®Google Scholar
• FuhrRVaidyaSKhindriSPharmacokinetics (PK) of indacaterol acetate and mometasone furoate delivered alone or in combination following once daily inhalation in healthy subjectsEur Respir J201444Suppl 58P903
   Google Scholar
• BeasleyRWDonohueJFMehtaREffect of once-daily indacaterol maleate/mometasone furoate on exacerbation risk in adolescent and adult asthma: a double-blind randomised controlled trialBMJ Open201552e006131
   PubMed Web of Science ®Google Scholar
• KornSBuhlREfficacy of a fixed combination of ciclesonide and formoterol: the EXCITED-studyRespir Med20121061576721890335
   PubMed Web of Science ®Google Scholar
• PapiABlasiFCanonicaGWFluticasone propionate/formoterol: A fixed-combination therapy with flexible dosageEur J Intern Med201425869570025051902
   PubMed Web of Science ®Google Scholar
• McKeageKFluticasone propionate/formoterol fumarate: a review of its use in persistent asthmaDrugs201373219520623397367
   PubMed Web of Science ®Google Scholar
• KarnerCCatesCJLong-acting beta(2)-agonist in addition to tiotropium versus either tiotropium or long-acting beta(2)-agonist alone for chronic obstructive pulmonary diseaseCochrane Database Syst Rev20124CD00898922513969
   PubMed Web of Science ®Google Scholar
• KarnerCCatesCJThe effect of adding inhaled corticosteroids to tiotropium and long-acting beta(2)-agonists for chronic obstructive pulmonary diseaseCochrane Database Syst Rev2011CD00903921901729
   PubMed Web of Science ®Google Scholar
• ShortPMWilliamsonPAElderDHLipworthSISchembriSLipworthBJThe impact of tiotropium on mortality and exacerbations when added to inhaled corticosteroids and long-acting β-agonist therapy in COPDChest20121411818621799028
   PubMed Web of Science ®Google Scholar
• LeeTAWilkeCJooMOutcomes associated with tiotropium use in patients with chronic obstructive pulmonary diseaseArch Intern Med2009169151403141019667304
   PubMed Web of Science ®Google Scholar
• HananiaNACraterGDMorrisANEmmettAHO’DellDMNiewoehnerDEBenefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPDRespir Med201210619110122040533
   PubMed Web of Science ®Google Scholar
• WelteTMiravitllesMHernandezPEfficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2009180874175019644045
   PubMed Web of Science ®Google Scholar
• ChatterjeeAShahMD’SouzaAOBechtelBCraterGDalalAAObservational study on the impact of initiating tiotropium alone versus tiotropium with fluticasone propionate/salmeterol combination therapy on outcomes and costs in chronic obstructive pulmonary diseaseRespir Res2012131522340019
   PubMed Web of Science ®Google Scholar
• JungKSParkHYParkSYKorean Academy of Tuberculosis and Respiratory Diseases study group; Korea Chronic Obstructive Pulmonary Disease study groupComparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled studyRespir Med2012106338238921975275
   PubMed Web of Science ®Google Scholar
• AaronSDVandemheenKLFergussonDCanadian Thoracic Society/Canadian Respiratory Clinical Research ConsortiumTiotropium in combination with placebo, salmeterol, or fluticasonesalmeterol for treatment of chronic obstructive pulmonary disease: a randomized trialAnn Intern Med2007146854555517310045
   PubMed Web of Science ®Google Scholar
• HughesADJonesLHDual-pharmacology muscarinic antagonist and β2 agonist molecules for the treatment of chronic obstructive pulmonary diseaseFuture Med Chem20113131585160521942250
   PubMed Web of Science ®Google Scholar
• SturtonGFitzgeraldMPhosphodiesterase 4 inhibitors for the treatment of COPDChest20021215 Suppl192S196S12010850
   PubMed Web of Science ®Google Scholar
• BarnesPJEmerging pharmacotherapies for COPDChest200813461278128619059958
   PubMed Web of Science ®Google Scholar
• PageCPSpinaDSelective PDE inhibitors as novel treatments for respiratory diseasesCurr Opin Pharmacol201212327528622497841
   PubMed Web of Science ®Google Scholar
• RennardSKnobilKRabeKFThe efficacy and safety of cilomilast in COPDDrugs200868Suppl 235719105585
   PubMed Web of Science ®Google Scholar
• PinnerNAHamiltonLAHughesARoflumilast: a phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary diseaseClin Ther2012341566622284994
   PubMed Web of Science ®Google Scholar
• RabeKFBatemanEDO’DonnellDWitteSBredenbrökerDBethkeTDRoflumilast – an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trialLancet2005366948556357116099292
   PubMed Web of Science ®Google Scholar
• CalverleyPMRabeKFGoehringUMKristiansenSFabbriLMMartinezFJM2-124 and M2-125 study groupsRoflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trialsLancet2009374969168569419716960
   PubMed Web of Science ®Google Scholar
• FabbriLMCalverleyPMIzquierdo-AlonsoJLM2-127 and M2-128 study groupsRoflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trialsLancet2009374969169570319716961
   PubMed Web of Science ®Google Scholar
• BayeJRoflumilast (daliresp): a novel phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary diseaseP T201237314916122605906
   PubMedGoogle Scholar
• GuptaSSide-effects of roflumilastLancet20123799817710711 author reply 711–71222364756
   PubMed Web of Science ®Google Scholar
• MonsóERuizJRosellABacterial infection in chronic obstructive pulmonary disease. A study of stable and exacerbated outpatients using the protected specimen brushAm J Respir Crit Care Med19951524 Pt 1131613207551388
   PubMed Web of Science ®Google Scholar
• SolerNTorresAEwigSBronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilationAm J Respir Crit Care Med19981575 Pt 1149815059603129
   PubMed Web of Science ®Google Scholar
• PelaRMarchesaniFAgostinelliCAirways microbial flora in COPD patients in stable clinical conditions and during exacerbations: a bronchoscopic investigationMonaldi Arch Chest Dis19985332622679785808
   PubMedGoogle Scholar
• AnthonisenNRManfredaJWarrenCPHershfieldESHardingGKNelsonNAAntibiotic therapy in exacerbations of chronic obstructive pulmonary diseaseAnn Intern Med198710621962043492164
   PubMed Web of Science ®Google Scholar
• WenzelRPFowlerAA3rdEdmondMBAntibiotic prevention of acute exacerbations of COPDN Engl J Med2012367434034722830464
   PubMed Web of Science ®Google Scholar
• PomaresXMontónCEspasaMCasabonJMonsóEGallegoMLong-term azithromycin therapy in patients with severe COPD and repeated exacerbationsInt J Chron Obstruct Pulmon Dis2011644945622003290
   PubMed Web of Science ®Google Scholar
• RamosFLCrinerGJUse of long-term macrolide therapy in chronic obstructive pulmonary diseaseCurr Opin Pulm Med201420215315824378875
   PubMed Web of Science ®Google Scholar
• UzunSDjaminRSKluytmansJAAzithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trialLancet Respir Med20142536136824746000
   PubMed Web of Science ®Google Scholar
• BerkhofFFDoornewaard-ten HertogNEUilSMKerstjensHAvan den BergJWAzithromycin and cough-specific health status in patients with chronic obstructive pulmonary disease and chronic cough: a randomised controlled trialRespir Res20131412524229360
   PubMed Web of Science ®Google Scholar
• AlbertRKConnettJBaileyWCCOPD Clinical Research NetworkAzithromycin for prevention of exacerbations of COPDN Engl J Med2011365868969821864166
   PubMed Web of Science ®Google Scholar
• HanMKTayobNMurraySPredictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapyAm J Respir Crit Care Med2014189121503150824779680
   PubMed Web of Science ®Google Scholar
• RayWAMurrayKTHallKArbogastPGSteinCMAzithromycin and the risk of cardiovascular deathN Engl J Med2012366201881189022591294
   PubMed Web of Science ®Google Scholar
• PetersJAnzuetoAAzithromycin once daily for 1 year reduced acute COPD exacerbationsAnn Intern Med20121562JC1J1022250172
   PubMed Web of Science ®Google Scholar
• ChapmanSJAntibiotic prevention of acute exacerbations of COPDN Engl J Med2012367191866 author reply 186723134401
   PubMedGoogle Scholar
• Garcia-VidalCViasusDCarratalàJAntibiotic prevention of acute exacerbations of COPDN Engl J Med2012367191866 author reply 186723134400
   PubMedGoogle Scholar
• SchwarzDGAntibiotic prevention of acute exacerbations of COPDN Engl J Med2012367191865 author reply 186723134399
   PubMedGoogle Scholar
• SiegelDAntibiotic prevention of acute exacerbations of COPDN Engl J Med2012367191865 author reply 186723134398
   PubMedGoogle Scholar
• ZaidiNNawabQAntibiotic prevention of acute exacerbations of COPDN Engl J Med20123671918641865 author reply 186723134397
   PubMedGoogle Scholar
• DiNicolantonioJJAzithromycin for prevention of exacerbations of COPDN Engl J Med2011365232235 author reply 223622150047
   PubMed Web of Science ®Google Scholar
• HahnDLAzithromycin for prevention of exacerbations of COPDN Engl J Med20113652322362236 author reply 2236–223722150048
   PubMed Web of Science ®Google Scholar
• SethiSJonesPWTheronMSPULSE Study groupPulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trialRespir Res2010111020109213
   PubMed Web of Science ®Google Scholar
• CrinerGJConnettJEAaronSDCOPD Clinical Research Network; Canadian Institutes of Health ResearchSimvastatin for the prevention of exacerbations in moderate-to-severe COPDN Engl J Med2014370232201221024836125
   PubMed Web of Science ®Google Scholar
• MorettoNCarusoPBoscoRCHF6001 I: a novel highly potent and selective phosphodiesterase 4 inhibitor with robust anti-inflammatory activity and suitable for topical pulmonary administrationJ Pharmacol Exp Ther2015352355956725576075
   PubMed Web of Science ®Google Scholar
• FranciosiLGDiamantZBannerKHEfficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trialsLancet Respir Med20131971472724429275
   PubMed Web of Science ®Google Scholar
• MateraMGPageCCazzolaMPDE inhibitors currently in early clinical trials for the treatment of asthmaExpert Opin Investig Drugs201423912671275
   PubMed Web of Science ®Google Scholar
• KobayashiYWadaHRossiosCA novel macrolide solithromycin exerts superior anti-inflammatory effect via NF-κB inhibitionJ Pharmacol Exp Ther20133451768423359665
   PubMed Web of Science ®Google Scholar
• DavisSSScobieSInglisAThe effect of sulphydryl compounds and cross linking agents on the viscous and viscoelastic properties of mucusBiorheology1975123–42252321125
   PubMed Web of Science ®Google Scholar
• SadowskaAMN-Acetylcysteine mucolysis in the management of chronic obstructive pulmonary diseaseTher Adv Respir Dis20126312713522361928
   PubMed Web of Science ®Google Scholar
• SheffnerALThe reduction in vitro in viscosity of mucoprotein solutions by a new mucolytic agent, N-acetyl-L-cysteineAnn N Y Acad Sci196310629831013977050
   PubMed Web of Science ®Google Scholar
• MataMRuizACerdaMOral N-acetylcysteine reduces bleomycin-induced lung damage and mucin Muc5ac expression in ratsEur Respir J200322690090514680076
   PubMed Web of Science ®Google Scholar
• ShenYCaiWLeiSZhangZEffect of high/low dose N-acetylcysteine on chronic obstructive pulmonary disease: a systematic review and meta-analysisCOPD201411335135824378052
   PubMedGoogle Scholar
• CazzolaMMateraMGN-acetylcysteine in COPD may be beneficial, but for whom?Lancet Respir Med20142316616724621673
   PubMed Web of Science ®Google Scholar
• ZhengJPWenFQBaiCXPANTHEON study groupTwice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trialLancet Respir Med20142318719424621680
   PubMed Web of Science ®Google Scholar
• TurnerRDBothamleyGHN-acetylcysteine for COPD: the evidence remains inconclusiveLancet Respir Med201424e324717631
   PubMed Web of Science ®Google Scholar
• RennardSIDaleDCDonohueJFCXCR2 Antagonist MK-7123. A phase 2 proof-of-concept trial for chronic obstructive pulmonary diseaseAm J Respir Crit Care Med201519191001101125695403
   PubMed Web of Science ®Google Scholar
• KhorasaniNBakerJJohnsonMChungKFBhavsarPKReversal of corticosteroid insensitivity by p38 MAPK inhibition in peripheral blood mononuclear cells from COPDInt J Chron Obstruct Pulmon Dis20151028329125678784
   PubMed Web of Science ®Google Scholar
• MacNeeWAllanRJJonesIDe SalvoMCTanLFEfficacy and safety of the oral p38 inhibitor PH-797804 in chronic obstructive pulmonary disease: a randomised clinical trialThorax201368873874523539534
   PubMed Web of Science ®Google Scholar
• PfizerStudy To Evaluate The Efficacy And Safety Of PH-797804 For 12 Weeks In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD) On A Background Of Tiotropium Bromide Available from: https://clinicaltrials.gov/ct2/show/NCT1543919. NLM identifier: NCT1543919Accessed June 11, 2015
   Google Scholar
• WatzHBarnacleHHartleyBFChanREfficacy and safety of the p38 MAPK inhibitor losmapimod for patients with chronic obstructive pulmonary disease: a randomised, double-blind, placebo-controlled trialLancet Respir Med201421637224461903
   PubMed Web of Science ®Google Scholar
• NormanPInvestigational p38 inhibitors for the treatment of chronic obstructive pulmonary diseaseExpert Opin Investig Drugs2015243383392
   PubMed Web of Science ®Google Scholar
• KodguleRVaidyaASalviSNewer therapies for chronic obstructive pulmona diseaseJ Assoc Physicians India201260Suppl81323155806
   PubMedGoogle Scholar
• ChurgAWangRWangXOnnervikPOThimKWrightJLEffect of an MMP-9/MMP-12 inhibitor on smoke-induced emphysema and airway remodelling in guinea pigsThorax200762870671317311841
   PubMed Web of Science ®Google Scholar
• CaramoriGAdcockIMDi StefanoAChungKFCytokine inhibition in the treatment of COPDInt J Chron Obstruct Pulmon Dis2014939741224812504
   PubMed Web of Science ®Google Scholar
• AstraZenecaEfficacy and Safety Study of Benralizumab in Adults and Adolescents Inadequately Controlled on Inhaled Corticosteroid Plus Long-acting β2 Agonist Available from: https://clinicaltrials.gov/ct2/show/NCT1914757?term=NCT1914757&rank=1. NLM identifier: NCT1914757Accessed June 11, 2015
   Google Scholar
• AstraZenecaStudy to Evaluate the Efficacy and Safety of Benralizumab in Adult Patients With Mild to Moderate Persistent Asthma Available from: https://clinicaltrials.gov/ct2/show/NCT2322775?term=NCT2322775&rank=1. NLM identifier: NCT2322775Accessed June 11, 2015
   Google Scholar
• AstraZenecaBenralizumab Efficacy in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History (GALATHEA) Available from: https://clinicaltrials.gov/ct2/show/NCT2138916?term=NCT2138916&rank=1. NLM identifier: NCT2138916Accessed June 11, 2015
   Google Scholar
• AstraZenecaEfficacy and Safety Study of Benralizumab to Reduce OCS Use in Patients With Uncontrolled Asthma on High Dose Inhaled Corticosteroid Plus LABA and Chronic OCS Therapy Available from: https://clinicaltrials.gov/ct2/show/NCT2075255?term=NCT2075255&rank=1. NLM identifier: NCT2075255Accessed June 11, 2015
   Google Scholar
• AstraZenecaEfficacy and Safety Study of Benralizumab Added to High-dose Inhaled Corticosteroid Plus LABA in Patients With Uncontrolled Asthma Available from: https://clinicaltrials.gov/ct2/show/NCT1928771?term=NCT1928771&rank=1. NLM identifier: NCT1928771Accessed June 11, 2015
   Google Scholar
• GlaxoSmithKlineA Phase 3a, Repeat Dose, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic Subjects Available from: https://clinicaltrials.gov/ct2/show/NCT2135692?term=NCT2135692&rank=1. NLM identifier: NCT2135692Accessed June 11, 2015
   Google Scholar
• GlaxoSmithKlineMepolizumab Steroid-Sparing Study in Subjects With Severe Refractory Asthma Available from: https://clinicaltrials.gov/ct2/show/NCT1691508?term=NCT1691508&rank=1. NLM identifier: NCT1691508Accessed June 11, 2015
   Google Scholar
• GlaxoSmithKlineA Study to Determine Long-term Safety of Mepolizumab in Asthmatic Subjects Available from: https://clinicaltrials.gov/ct2/show/NCT1842607?term=NCT1842607&rank=1. NLM identifier: NCT1842607Accessed June 11, 2015
   Google Scholar
• McMaster UniversityMepolizumab in Chronic Obstructive Pulmonary Diseases (COPD) With Eosinophilic Bronchitis Available from: https://clinicaltrials.gov/ct2/show/NCT1463644?term=NCT1463644&rank=1. NLM identifier: NCT1463644Accessed June 11, 2015
   Google Scholar
• GlaxoSmithKlineEfficacy and Safety of Mepolizumab as an Add-on Treatment in Chronic Obstructive Pulmonary Disease (COPD) Available from: https://clinicaltrials.gov/ct2/show/NCT2105961?term=NCT2105961&rank=1. NLM identifier: NCT2105961Accessed June 11, 2015
   Google Scholar
• GlaxoSmithKlineEfficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinophilic Asthma on Markers of Asthma Control Available from: https://clinicaltrials.gov/ct2/show/NCT2281318?term=NCT2281318&rank=1. NLM identifier: NCT2281318Accessed June 11, 2015
   Google Scholar
• GlaxoSmithKlineStudy to Evaluate Efficacy and Safety of Mepolizumab for Frequently Exacerbating Chronic Obstructive Pulmonary Disease (COPD) Patients Available from: https://clinicaltrials.gov/ct2/show/NCT2105948?term=NCT2105948&rank=1. NLM identifier: NCT2105948Accessed June 11, 2015
   Google Scholar
• BrightlingCEBleeckerERPanettieriRAJrBenralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a studyLancet Respir Med201421189190125208464
   PubMed Web of Science ®Google Scholar
• BusseWWHolgateSKerwinERandomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthmaAm J Respir Crit Care Med2013188111294130224200404
   PubMed Web of Science ®Google Scholar
• SriskantharajahSHamblinNWorsleySCalverARHesselEMAmourATargeting phosphoinositide 3-kinase δ for the treatment of respiratory diseasesAnn N Y Acad Sci20131280353923551101
   PubMed Web of Science ®Google Scholar
• WangLYangJGuoLUse of a soluble epoxide hydrolase inhibitor in smoke-induced chronic obstructive pulmonary diseaseAm J Respir Cell Mol Biol201246561462222180869
   PubMed Web of Science ®Google Scholar
• StolkJStockleyRAStoelBCRandomised controlled trial for emphysema with a selective agonist of the γ-type retinoic acid receptorEur Respir J201240230631222282548
   PubMed Web of Science ®Google Scholar
• StolkJCooperBGStoelBRetinoid treatment of Emphysema in Patients on the Alpha-1 International Registry. The REPAIR study: study design, methodology and quality control of study assessmentsTher Adv Respir Dis20104631933220926506
   PubMedGoogle Scholar
• StessukTRuizMAGrecoOTBilaquiARibeiro-PaesMJRibeiro-PaesJTPhase I clinical trial of cell therapy in patients with advanced chronic obstructive pulmonary disease: follow-up of up to 3 yearsRev Bras Hematol Hemoter201335535235724255620
   PubMedGoogle Scholar